IMMUNE CELLS WITH INACTIVATED SUV39H1 AND MODIFIED TCR

The present disclosure relates to an improved immune cell expressing an antigen-specific receptor such as a CAR or TCR, in which SUV39H1 is inactivated, optionally combined with disruption of the TRAC locus and/or deletion of one or more ITAMs. The disclosure also provides compositions comprising su...

Full description

Saved in:
Bibliographic Details
Main Authors JHUN, Kevin, WEI, Yao, SOMARAJU, Madhavi Latha, VANBUREN, Kayla, BOHINEUST, Armelle, YINGZHE LI, Angela, SAITAKIS, Michael, NAIR GUPTA, Priyanka, GIAVRIDIS, Theodoros, PANDA, Saswati, GAUDET, Francois
Format Patent
LanguageEnglish
French
German
Published 06.11.2024
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to an improved immune cell expressing an antigen-specific receptor such as a CAR or TCR, in which SUV39H1 is inactivated, optionally combined with disruption of the TRAC locus and/or deletion of one or more ITAMs. The disclosure also provides compositions comprising such cells, methods of producing such cells, and uses of such cells in adoptive cell therapy, e.g. in cancer or inflammatory diseases.
Bibliography:Application Number: EP20220844655